Literature DB >> 2307481

Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats.

J Zielasek1, V Burkart, P Naylor, A Goldstein, U Kiesel, H Kolb.   

Abstract

Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. Diabetes development was enhanced in the subline with a low intrinsic diabetes risk and suppressed in the subline with a high diabetes risk. IL-2 treatment started between 35 and 42 days of age and lasted for 3 months. In subline 1, diabetes incidence increased from 23% to 53% (P less than 0.01), in subline 2 it decreased from 73% to 32% (P less than 0.01). The two sublines differed in serum levels of factors controlling IL-2 synthesis and activity. Mean IL-2 inhibitory activity was higher in subline 2 (between 140% and 290% of levels in subline 1, P less than 0.01). Conversely, mean concentrations of thymosin alpha 1 and beta 4 were higher in subline 1 (between 140% and 200% of levels in subline 2, P less than 0.01). Thus the two sublines differ in their response to exogenous IL-2 and also in serum levels of mediators affecting availability of IL-2. We conclude that an internal network of hormonal factors, including IL-2, contributes to the control of diabetes development in the BB rat.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307481      PMCID: PMC1385591     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Contra-IL 2; a suppressor lymphokine that inhibits IL 2 activity.

Authors:  T Maki; S Satomi; M Gotoh; A P Monaco
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

2.  Serum IL-2 inhibitor in mice. II. Molecular characteristics.

Authors:  D Male; R Lelchuk; S Curry; G Pryce; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

Review 3.  Thymosin modulates immune and endocrine events.

Authors:  P H Naylor; A L Goldstein
Journal:  Prog Clin Biol Res       Date:  1988

4.  Serum IL-2 inhibitor in mice. I. Increase during infection.

Authors:  R Lelchuk; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

5.  Recombinant interleukin 2 enhances spontaneous insulin-dependent diabetes in BB rats.

Authors:  H Kolb; J Zielasek; U Treichel; G Freytag; M Wrann; U Kiesel
Journal:  Eur J Immunol       Date:  1986-02       Impact factor: 5.532

Review 6.  Serum inhibitors of interleukin-2.

Authors:  E J Kucharz; J S Goodwin
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

7.  T-lymphocyte subpopulations in insulin-dependent (type I) diabetes mellitus.

Authors:  O Pontesilli; H P Chase; P Carotenuto; M J Herberger; A R Hayward
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

8.  Effect of interleukin-2 on diabetes in the BB/Wor rat.

Authors:  D Burstein; E S Handler; J Schindler; J Seals; J P Mordes; A A Rossini
Journal:  Diabetes Res       Date:  1987-08

9.  Induction and upregulation by interleukin 2 of high-affinity interleukin 2 receptors on thymocytes and T cells.

Authors:  G H Reem; N H Yeh; D L Urdal; P L Kilian; J J Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Thymosin and the spontaneously diabetic BB rat.

Authors:  W E Winter; V Robbins; M Elder; D Barrett; N Martin; N K Maclaren
Journal:  Autoimmunity       Date:  1988       Impact factor: 2.815

View more
  4 in total

1.  Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes.

Authors:  M Moritani; K Yoshimoto; S Ii; M Kondo; H Iwahana; T Yamaoka; T Sano; N Nakano; H Kikutani; M Itakura
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

2.  Imbalance of the interleukin 2 system in children with IDDM.

Authors:  T Tomoda; T Kurashige; T Taniguchi
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

3.  Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases.

Authors:  H C Jeffery; L E Jeffery; P Lutz; M Corrigan; G J Webb; G M Hirschfield; D H Adams; Y H Oo
Journal:  Clin Exp Immunol       Date:  2017-03-20       Impact factor: 4.330

4.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.